National Blood Clot Alliance Medical and Scientific Advisory Board
Jack Ansell, MD. Chairman of the Department of Medicine at Lenox Hill Hospital, NY
Dr. Ansell is the Chairman of the Department of Medicine at Lenox Hill Hospital in New York City. Before joining Lenox Hill Hospital, Dr. Ansell was Professor of Medicine at Boston University School of Medicine and Vice Chairman for Clinical Affairs of the Department of Medicine.
See related news story.
After receiving his medical degree from the University of Virginia School of Medicine in Charlottesville, Virginia, Dr. Ansell completed an internship and residency at Tufts New England Medical Center in Boston, Massachusetts. Dr. Ansell then completed a fellowship in hematology at Boston University and in hematology/hemostasis at Boston’s Veterans Administration Hospital.
Dr. Ansell’s main areas of interest and research include hemostasis and thrombosis, with a special emphasis on thrombotic disorders and antithrombotic therapy. He has had a continued interest and involvement in the application of new modes of delivering and monitoring anticoagulants, particularly in the management of oral anticoagulant therapy.
Dr. Ansell has approximately 170 publications in notable journals such as Annals of Internal Medicine, The New England Journal of Medicine, and The Journal of the American Medical Association. His publishing activity includes reviews, editorials, textbooks, videos, abstracts and letters. He serves as an associate editor for the Journal of Thrombosis and Thrombolysis and as an editorial consultant for such journals as The New England Journal of Medicine, Blood, Thrombosis and Haemostasis, and Circulation.
Dr. Ansell is the founder and Chair of the Anticoagulation Forum, a network of anticoagulation clinics throughout North America, and is a member of a number of professional organizations including the American College of Physicians (Fellow); the American Society of Hematology; the International Society of Thrombosis and Hemostasis and its Scientific Subcommittee on Haemostasis Testing; the American Heart Association (Fellow), and the American Medical Association. Dr. Ansell also serves as Chair of the Committee on Managing Oral Anticoagulation for the American College of Chest Physicians Consensus Conference on Antithrombotic Therapy.
Kenneth A. Bauer, MD, Harvard Medical School, Boston, MA
Dr
Bauer is Professor of Medicine, Harvard Medical School. His hospital
positions include Chief, Hematology Section, VA Boston Healthcare System,
and Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical
Center in Boston. Dr Bauer received his medical degree from Stanford
University School of Medicine in Stanford, California. He completed his
residency in medicine at the University of Chicago Hospitals and Clinics in
Illinois. He was a Fellow in Medical Oncology and a Clinical/Research
Fellow in the Division of Thrombosis and Hemostasis at Dana Farber Cancer
Institute and was also a Clinical/Research Fellow in the Hematology-Oncology
Division at Beth Israel Deaconess Medical Center. Dr Bauer’s research
interests include elucidation of the mechanisms leading to the development
of a prethrombotic state and clinical evaluation of new antithrombotic
drugs. Dr Bauer previously served as Chairman of Council of the
International Society on Thrombosis and Haemostasis (ISTH) and
Vice-President and Scientific Program Chair (Clinical) for the XXIInd ISTH
Congress in Boston in July 2009. Dr Bauer has published over 200 original
reports, reviews, and book chapters.
Bruce Evatt, MD, Director, Division of Hereditary Blood Diseases (Retired)
As a hematologist interested in blood coagulation-associated diseases, Dr. Evatt has worked with hemophilia and thrombotic disorders since 1965, first at the Johns Hopkins Hospital in Baltimore and then the Centers for Disease Control in Atlanta beginning in 1976, when he established a national laboratory in hemostasis. He also served as a volunteer and Board of Directors member for Hemophilia of Georgia until the late 1980=s. His major accomplishments include identifying AIDS as a blood-borne disease affecting persons with hemophilia and blood-transfusion recipients, demonstrating that heat-treatment of clotting factor concentrates inactivates HIV, and identifying a new class of congenital clotting disorders, protein C deficiency. He has authored or co-authored more than 250 scientific or review articles. Presently, his major activity includes managing a national program directed at preventing complications of hemophilia and related bleeding and clotting disorders and thalassemia.
Current Academic Positions: Clinical Professor of Medicine, Emory University School of Medicine, Atlanta, Georgia
National Activities (Current & Past): National Blood Resource Education Program Coordinating Committee; FDA Blood and Blood Products Advisory Committee; National Hemophilia Foundation AIDS Task Force Committee; Public Health Service AIDS Task Force on Blood and Blood Products; American Society of Hematology Subcommittee on Hemostasis; American Society of Hematology Subcommittee on Clinical Laboratory Standards; National Committee for Clinical Laboratory Standards Subcommittee on Coagulation
International Activities: Member, Executive Committee, World Federation of Hemophilia (WFH); Vice-President Developing World, WFH; CDC Liaison to International Committee for Standardization in Haematology; CDC Liaison to International Society for Thrombosis and Hemostasis
Prior Positions: Investigator, Howard Hughes Medical Center; Assistant Professor of Medicine, John Hopkins School of Medicine; Chief Resident of Medicine, John Hopkins School of Medicine; Senior Resident of Medicine, John Hopkins School of Medicine; Osler Medical Service, John Hopkins School of Medicine
Education: University of Oklahoma; MD, University of Oklahoma Honors: American Society of Hematology Outstanding Lifetime Service Award; 2004 CDC Distinguished Service Award; Public Health Service Meritorious Service Award; Dr. L. Michael Kuhn Award for Outstanding Governmental Leadership; Dr. Murray Thelin Award for Distinguished Research; PHS Commendation Award; Stewart Wolfe Lectureship, University of Oklahoma; Public Health Service Hemophilia Association of New Jersey; The Francis S. Schwentker Award for Research, John Hopkins Medical School
Richard J. Friedman, MD, FRCSC
Richard
J. Friedman, MD, FRCSC, is Clinical Professor of Orthopaedic Surgery at the
Medical University of South Carolina in Charleston, Medical Director of
Charleston Orthopaedic Associates, and an Adjunct Professor of
Bioengineering at Clemson University. He is also Chairman of the Department
of Orthopaedic Surgery at Roper Hospital in Charleston, South Carolina.
Dr. Friedman received his MD degree in 1980 from the University of Toronto Faculty of Medicine and completed residencies in surgery at Massachusetts General Hospital and in orthopedic surgery at the Harvard Combined Orthopedic Residency Program in Boston. He also completed a clinical fellowship in surgery at Johns Hopkins University School of Medicine in Baltimore as well as clinical fellowships in surgery and orthopedic surgery at Harvard Medical School in Boston. Dr. Friedman is board certified in orthopedic surgery.
A member of the North American and International Hip and Knee Registry Steering Committees as well as consultant to the Orthopedic Device Review Panel of the US Food and Drug Administration, Dr. Friedman is a fellow of the American Academy of Orthopaedic Surgeons, American College of Surgeons, and Royal College of Physicians and Surgeons of Canada and a member of the American Orthopaedic Association, Academic Orthopaedic Society, American Shoulder and Elbow Surgeons, South Carolina Medical Association, South Carolina Orthopaedic Association and European Society for Surgery of the Shoulder and Elbow, among others. He is a reviewer for Journal of Bone and Joint Surgery, Clinical Orthopaedics and Related Research, Journal of Shoulder and Elbow Surgery, and Journal of Orthopaedic Research. Dr. Friedman also serves on the American Medical Association CPT Advisory Committee as well as the American Academy of Orthopaedic Surgeons CPT Coding Committee.
Dr. Friedman was the founder of the Orthopaedic Research Laboratory at MUSC, and has received over 50 research grants, most recently for clinical research studies involving joint replacement surgery. He has published over 200 peer reviewed scientific articles in such journals as the New England Journal of Medicine, Orthopedic Clinics of North America, Journal of Bone and Joint Surgery, Clinical Orthopaedics and Related Research, Journal of Shoulder and Elbow Surgery, Journal of Orthopaedic Research. and Biomaterial. Dr. Friedman has also written numerous book chapters and had over 150 scientific abstracts published. He has presented nationally and internationally at over 400 medical conferences. Dr. Friedman’s special areas of interests focus on total joint replacement, including hip, knee, shoulder and elbow; shoulder and elbow disorders and sports medicine; and arthroscopic surgery.
David Garcia, MD , Director of the Adult Hemophilia Treatment Program, Director of the Anticoagulation Management Service
Dr.
David Garcia is a Fellow in the Division of Hematology at the University of
Washington.
Dr. Garcia is the President of the Anticoagulation Forum, a national interest group focused on the prevention and treatment of thromboembolic disease. His primary research interests include the relationship of cancer and thrombosis, the treatment of warfarin-associated coagulopathy, and the risks and benefits of peri-procedural anticoagulation. Dr. Garcia has been an invited speaker at several international meetings and has authored or co-authored more than 30 peer-reviewed publications in high-impact journals such as Blood, Annals of Internal Medicine, Archives of Internal Medicine, Chest, Thrombosis and Thrombolysis, the British Journal of Hematology and the Journal of the American College of Cardiology.
John Heit, MD, FACP, FACC, Mayo Clinic, Rochester, MN
Dr. Heit is Professor of Medicine at the Mayo Clinic College of Medicine, where he serves in multiple capacities. He is the Director of the Mayo Clinic General, Special and DNA-diagnostic Coagulation Laboratories and Coagulation Clinic; Chair of the Division of Hematology Coagulation Disease Oriented Group and Program Director for the NIH K12 Vascular Medicine Clinical Research Training Program. Dr. Heit is a staff consultant within the Divisions of Cardiovascular Diseases (Section of Vascular Disease) and Hematology (Section of Hematology Research), Department of Internal Medicine and the Divisions of Hematopathology and Laboratory Genetics, Department of Laboratory Medicine and Pathology. Dr. Heit is the Founder and former Director of both the Mayo Clinic Thrombophilia Center and the Mayo Clinic Chronic Anticoagulation Management Clinic. He is also Co-Founder and Co-Director of the Mayo Clinic Special Coagulation DNA-diagnostic Laboratory.
He is the Principal Investigator on 5 NIH grants and Co-Investigator on 2 NIH grants, addressing the epidemiology (including the genetic epidemiology) and mechanisms of venous thromboembolism and thrombophilia in white and African-American populations, the role of estrogens and platelets in atherosclerosis and bleeding disorders in women.
Dr. Heit has written over 160 peer-reviewed articles, invited papers or book chapters. He has delivered presentations at various medical conferences in the US and abroad, and has served as a member of NIH study sections, as a member of the American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy since 1995, as a reviewer for 28 medical journals, as Associate Editor for the journal Thrombosis Research, and as Co-Chair of the National Quality Forum/Joint Commission Steering Committee on Venous Thromboembolism Prevention and Management. Dr. Heit is married, and has two children and six grandchildren.
Andra H. James, MD, MPH, Duke University, Durham, NC
Dr. Andra H. James is a maternal-fetal medicine specialist, Professor and Vice Chair of Research in the Department of Obstetrics and Gynecology at the University of Virginia. Her practice, research and publications focus on reproductive issues among women with bleeding and clotting disorders.
Dr. James is involved both nationally and internationally in activities to improve healthcare for women with bleeding and clotting disorders. Besides serving on the Medical and Scientific Advisory Board (MASAB) of NBCA, she currently serves on the Medical and Scientific Advisory Committee (MASAC) of the National Hemophilia Foundation (NHF). She is also Co-Chair of the Women’s Issues Scientific Subcommittee of the International Society on Haemostasis and Thrombosis, President of the Foundation for Women and Girls with Blood Disorders (FWGBD), and on the VWD & Rare Bleeding Disorders Committee of the World Federation of Hemophilia. She has served on the National Institutes of Health (NIH) National Heart Lung and Blood Institute’s Women with Bleeding Disorders Working Group and their Von Willebrand Disease Expert Panel.
Dr. James has published over 100 articles in various well known journals, as well as co-authored a book with Dr. Thomas L. Ortel and Dr. Victor F. Tapson, entitled 100 Questions and Answers About Deep Vein Thrombosis and Pulmonary Embolism, published in 2008.
Scott Kaatz, DO, MSc, FACP
.JPG)
Scott
Kaatz is the Chief Quality Officer and head of the Academic Hospital
Medicine program at Hurley Medical Center in Flint Michigan. He
attended medical school at Michigan State University and completed his
residency in internal medicine at Henry Ford Hospital. Later in his
career, he earned his Master’s degree in Evidence-Based Health Care from
Oxford University.
He has a long standing research interest in anticoagulation and thromboembolic disease and was the Medical Director of the Anticoagulation Clinics for the Henry Ford Health System in Detroit, MI for15 years.
Dr. Kaatz is a fellow of American College of Physicians, as well as a member of the Society for General Internal Medicine, the Society of Hospital Medicine, the International Society of Thrombosis and Heamostasis and the American Medical Association. He serves on the boards of the National Certification Board of Anticoagulation Providers, AC Forum and the Medical Scientific Advisory Board of the National Blood Clot Alliance.
He has participated in many research studies with an emphasis on anticoagulation and venous thromboembolism prevention, diagnosis and treatment; and has published numerous abstracts, articles and book chapter in this field.
Kenneth Mann, PhD, University of Vermont, Burlington, VT
Dr. Mann received his Ph.D. in Biochemistry (C.S. Vestling) at the University of Iowa. After additional post- doctoral training in physical biochemistry at Duke University (C. Tanford), he moved to the University of Minnesota as an Assistant Professor. His interest in applying Physical Biochemistry techniques to elucidating the varied physical and functional interactions of proteins in the blood coagulation process was encouraged by a joint appointment at the Mayo Clinic (Mayo Medical School), where he achieved the rank of Professor of Biochemistry and Medicine and became Vice Chair of the Department of Medicine. He came to the University of Vermont in 1984 as Professor and Chair of Biochemistry, and he relinquished the Chair in 2005.
Dr. Mann’s research interests involve fundamental mechanisms of blood
coagulation and its regulation and extensions of this research endeavor to
translational contribution to vascular medicine. He has published over 450
original research articles and book chapters." Add at the end "He received
the "Henri Chaigneau Prize from the Association Francaise des Hemophiles in
2010.
Gregory Maynard, Clinical Professor and Chief, Division of Hospital Medicine, UC San Diego Director, UCSD Center for Innovation and Improvement Science
Greg
Maynard is a Clinical Professor of Medicine and Chief of the division of
Hospital Medicine at the University of California, San Diego. He is active
on both a local and national level in many efforts to improve the quality
and safety of the care delivered to inpatients. Dr. Maynard’s special
interests include optimizing prevention and management of venous
thromboembolism (VTE), improving glycemic control and reducing hypoglycemia
in the hospital, and transitions of care. Dr. Maynard’s research interests
parallel his QI efforts, and he is principal investigator or otherwise
involved in several funded research efforts. He acts as a leader and mentor
in the Society of Hospital Medicine (SHM), AHRQ, ASHP, and IHI national
collaboratives to improve VTE prevention He is a mentor / investigator for
Project BOOST, an SHM initiative to improve transitions in care, and is also
a mentor / investigator for the SHM Glycemic Control collaborative. He
acted as the lead of the SHM Glycemic Control Task Force, generating the SHM
Glycemic Control Resource Room and the supplement in Journal of Hospital
Medicine reflecting the Task Force work, and has published numerous peer
reviewed papers on the subject. Dr. Maynard was recently recognized as one
of ACP Hospitalist's top hospitalists, and San Diego county “Top Doc”, and
has been recognized nationally for his work in Quality Improvement /
Research by the Society of Hospital Medicine, the National Association of
Public Hospitals, the Venous Disease Coalition, and the North American
Thrombosis Forum. He was recently named as the Director of the UCSD Center
for Innovation and Improvement Science.
Stephan Moll, MD, University of North Carolina School of Medicine
Dr.
Stephan Moll received his medical school training in Freiburg, Germany, and
London, England. He trained 5 years in Medicine and Hematology-Oncology at
Duke University in Durham, NC and one year in Clinical Coagulation at the
University of North Carolina in Chapel Hill (UNC). He has been on the
faculty at the University of North Carolina in the Department of Medicine,
Division of Hematology-Oncology, since 1999.
Dr. Moll is a clinician, clinical researcher, and clinical educator. Most of his time is spent treating patients with clotting disorders, conducting clinical research relating to thrombosis and thrombophilia, and educating healthcare providers and patients on blood clotting issues. Dr. Moll is one of the founding members of the National Blood Clot Alliance, was NBCA’s first Chair of the Medical and Scientific Advisory Board and first Medical Director. Dr. Moll has 4 children. He likes hiking, bicycling and traveling.
Gerald V. Naccarelli
.jpg)
Gerald
V. Naccarelli M.D. was born in Philadelphia, Pa, received his B.S. in
Biology from St. Joseph's University and his M.D. degree from the
Pennsylvania State University College of Medicine in Hershey. He was an
Internal Medicine Resident at the North Carolina Baptist Hospital/Bowman
Gray School of Medicine (Wake Forest University). He was a Fellow in
Cardiology and Chief Resident in Medicine at the Penn State University
College of Medicine followed by a UPSHS postdoctoral Fellow in Cardiac
Electrophysiology at the Indiana University School of Medicine. Prior to his
current position at Hershey, he was Director of Clinical Electrophysiology
and Vice-Chairman of Cardiology at the University of Texas Medical School at
Houston. In 1995 he moved to Hershey and currently is the Bernard Trabin
Chair in Cardiology, Professor of Medicine, Chief of the Division of
Cardiology, and Associate Clinical Director of the Heart and Vascular
Institute at the Pennsylvania State University College of Medicine/Milton S.
Hershey Medical Center.
Dr. Naccarelli had been a member of multiple
national committees of the American Heart Association (AHA), American
College of Cardiology (ACC) and the Heart Rhythm Society (HRS). He is
past-president of NASPE (HRS) and a past-member of the Board of Trustees of
the American College of Cardiology and HRS. He served on the ABIM
Subspecialty Board on Cardiovascular Diseases from 1999-2005 and currently
is the Chair of the ABIM Cardiovascular Diseases SEP Committee. He was a
charter member of CMS’ Ambulatory Payment Classification (APC) advisory
panel. He is an elected member of the Association of University
Cardiologists (AUC) and member and Past-President of the Association of the
Professors of Cardiology (APC).
Dr. Naccarelli is internationally recognized for his clinical, teaching and
research contributions. He has been listed in the best Doctors of
America (Cardiovascular Diseases - Electrophysiology) since 1992 and
America’s Top Doctors (Castle Connolly) since 2001. Dr. Naccarelli has
trained 27 fellows in cardiac electrophysiology and over 125 fellows in
Cardiology over his 31 years of clinical practice.
Dr. Naccarelli’s research interests are in atrial fibrillation, clinical arrhythmia trials, implantable devices for treating arrhythmias and congestive heart failure, antiarrhythmic drug development and autonomic aspects of arrhythmogenesis. He has published over 550 peer review papers, book chapters, reviews and abstracts and is the author of 3 books. Dr Naccarelli has been involved in the clinical development and approval of all the antiarrhythmic agents released in the USA over the last 30 years. He has been an active consultant to over 25 companies in medical industry and is currently on the steering committee of 6 major clinical trials.
He is a recipient of the Paul Dudley White Award from the American Heart Association and the Nycomed Amersham Award for Excellence Honoring Leadership, Achievement and Commitment to the Profession from the American College of Cardiovascular Administrators and the 2012 Clarence E. Shaffrey, S.J. Award, from St. Joseph’s University, in recognition of his service and outstanding achievement in the medical profession. He is currently on the editorial board of 8 scientific journals in addition to being Associate Editor of the Journal of Interventional Cardiac Electrophysiology and a past Associate editor of Circulation.
Dr. Naccarelli and his wife, Terry, have a daughter, Michele, and a son, Matthew both of whom work in Philadelphia. Outside of medicine, Dr. Naccarelli's hobbies include golf, hockey card collecting, enology and playing the guitar.
Edith A. Nutescu, Pharm.D., FCCP
Edith A. Nutescu, Pharm.D., FCCP, is Clinical Professor in the Department of Pharmacy Practice and Center for Pharmacoeconomic Research at the University of Illinois at Chicago College of Pharmacy. She also serves as the Clinical Manager of the Antithrombosis Center at the University of Illinois at Chicago Medical Center. Dr. Nutescu earned her Pharm.D. degree with high honors at the University of Illinois at Chicago College of Pharmacy. After graduation, Dr Nutescu went on to complete an American Society of Health-System Pharmacists (ASHP)–accredited Pharmacy Practice Residency at Lutheran General Hospital–Advocate Health Care and a Primary Care Specialty Residency at the University of Illinois at Chicago Medical Center. As a clinician and educator, Dr. Nutescu has contributed extensively to the care of patients and the education of students and health care providers on topics related to cardiovascular therapeutics. Dr. Nutescu maintains an active clinical practice and research program. Her research and practice interests are in the areas of comparative effectiveness, health services and outcomes, with emphasis in cardiovascular diseases, stroke, thrombosis, and antithrombotic therapies. Dr Nutescu has authored or co-authored over 100 scientific articles, book chapters, and abstracts published in the science and medical literature and has served as a reviewer for the literature in her field. Dr. Nutescu’s research has been funded by the Department of Health and Human Services and the National Center for Research Resources and is a recipient of the Ruth L. Kirchstein National Research Service Award for 2009-2011. Dr. Nutescu is the recipient of the American College of Clinical Pharmacy’s 2009 Clinical Practice Award and the American Society of Health System Pharmacists, Section of Home and Ambulatory Care Practitioners 2010 Distinguished Service Award.
Lynn B. Oertel, M.S. ANP-C, CACP
Lynn
B. Oertel, M.S. ANP-C, CACP, is a clinical nurse specialist with The
Anticoagulation Management Service at Massachusetts General Hospital in
Boston, Massachusetts. Massachusetts General Hospital has one of the
largest and most experienced warfarin management clinics in the United
States.
Ms. Oertel received her Master of Science in Nursing degree from Boston University. She has additional certification from the American Nurse’s Credentialing Center as an adult nurse practitioner. Ms. Oertel is a certified anticoagulation care provider (CACP) and is nationally recognized as an expert nurse clinician in anticoagulation therapy management. She has nearly 25 years of clinical and research experience related to anticoagulant therapy management.
Ms. Oertel is a founding member of the Board of Directors of the National Certification Board for Anticoagulation Providers, the only multidisciplinary national certification for anticoagulation care providers. She is currently a member of the Board of Directors of the Anticoagulation Forum and co-editor and chapter author of the third edition textbook Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines.
Gary E. Raskob, Ph. D., M.Sc. Dean, College of Public Health Professor, Epidemiology and Medicine University of Oklahoma Health Sciences Center
.JPG)
Gary
Raskob is Dean of the College of Public Health at the University of Oklahoma
Health Sciences Center, Oklahoma City, Oklahoma. He holds a joint academic
appointment as Professor in the Department of Biostatistics and
Epidemiology, College of Public Health, and in the Department of Medicine,
College of Medicine. His research and scholarly interests are in
the prevention, diagnosis and treatment of deep-vein thrombosis and
pulmonary embolism; the clinical development of antithrombotic drugs;
prevention research; evidence-based medicine; and the translation of
research evidence into practice and health policy.
Dr Raskob has participated extensively in clinical practice guideline
development for several specialty organizations including the American
Society of Hematology (ASH), the American College of Chest Physicians
(ACCP), the American Thoracic Society (ATS), and the American Society of
Clinical Oncology (ASCO). Dr Raskob has extensive experience in
regulatory aspects of clinical research and human research subject
protections, and in the data-safety monitoring of clinical trials. He serves
as a consultant in clinical research and drug development for the
pharmaceutical and biotechnology industry. Dr. Raskob has served as a member
of the external advisory panel on the “State of the Science” in thrombosis
and hemostasis for the National Heart, Lung and Blood Institute (NHLBI), and
as an advisor on thrombosis and blood disorders to the Centers for Disease
Control and Prevention (CDC).
Dr Raskob was recently elected to a second term on the Board of Directors of
the Association of Schools of Public Health (ASPH), which represents the 46
accredited schools of public health in the United States. He was also
elected by his fellow Deans to serve as Chair of the Legislative Committee
for this association, and in 2009, he testified on behalf of ASPH at the
hearings on health reform held by the US Senate Committee on Health,
Education, Labor and Pensions. Dr. Raskob also previously served as
Chair of the Committee on Public Health Preparedness, and was Co-Chair of
the Native American Task Force, co-sponsored by the Indian Health Service
and the National Indian Health Board.
Dr Raskob received his Ph.D. in pharmaceutical sciences from the University
of Oklahoma, a Master of Science (MSc) degree in clinical epidemiology and
health research methodology from McMaster University in Hamilton, Canada,
and a Bachelor of Science degree in pharmacology from the University of
Toronto, Canada. He is author or coauthor of more than 175 articles on
the prevention, diagnosis and treatment of thromboembolic disease.
FREDERICK R. RICKLES, MD, FACP, Professor of Medicine, Pediatrics and Pharmacology and Physiology, The George Washington University, Washington, DC
Dr.
Rickles received his MD degree from the University of Illinois and trained
in internal medicine and hematology at the University of Rochester School of
Medicine, Rochester, NY. He was Director of the Hemostasis and Thrombosis
Research Laboratory at Walter Reed Army Institute of Research from
1971-1974, and was on the faculty of the University of Connecticut School of
Medicine from 1974-93, where he was the American Red Cross Professor of
Medicine and Laboratory Medicine and Chief, Hematology-Oncology. From
1993-1998, he was Deputy Chief, Hematologic Diseases at the Centers for
Disease Control and Prevention, Professor of Medicine and Pediatrics at
Emory University and Director of the Emory Hemophilia and Thrombosis Center,
in Atlanta, GA. From 1998-2003, Dr. Rickles was Associate VP for Health
Research at The George Washington University and from 2003-2006, he was the
CEO of FASEB. Since 2006, Dr. Rickles is a consultant to the Healthcare
group of Noblis, a non-profit technology and science company working in the
public interest, and to Eisai, Johnson & Johnson, Genmab, ISIS and
Pharmacyclics on the development of new drugs for the prevention and
treatment of thrombosis and bleeding disorders. He is an Editor of the book
Cancer and Thrombosis and the author of over 120 papers in refereed
journals, 10 book chapters and 20 reviews in his areas of interest,
including hemophilia, von Willebrand Disease, rare coagulation disorders and
thrombosis in cancer. He continues to investigate the regulation of TF and
Vascular Endothelial Growth Factor gene expression in cancer and has
collaborated on the design of novel therapeutic agents that inhibit these
pathways. He has been on the editorial board of Thrombosis and Haemostasis,
Blood Coagulation and Fibrinolysis, Journal of Thrombosis and Hemostasis and
Supportive Cancer Therapy. Dr. Rickles has served on study sections for the
NIH, DoD, ACS and the AHA and was a founding Chairman of the Subcommittee on
Coagulation and Malignancy for the ISTH and served on the Subcommittee of
Vascular Biology and Thrombosis for the ASH. He is a member of AACR and was
VP for Medical and Scientific Affairs for the NHF and a founding member of
the Hemophilia and Thrombophilia Research Society.
Michael B. Streiff, MD, FACP
Associate
Professor of Medicine and Pathology
Associate Faculty, Armstrong Institute for Patient Safety and Quality Care
Medical Director, Johns Hopkins Anticoagulation Management Service and
Outpatient Clinics
Medical Director, Special Coagulation Laboratory
Chairman, Venous Thromboembolism Guideline Committee, National Comprehensive
Cancer Network
Johns Hopkins Medical Institutions
Baltimore, Maryland
Dr Streiff’s research focuses on the prevention and treatment of venous
thromboembolism (VTE) and evidence-based management of anticoagulation. He
chairs the Venous Thromboembolism Guideline Committee for the National
Comprehensive Cancer Center Network and has served on several international
consensus panels to develop evidence-based guidelines for the management of
VTE. As a member of the Johns Hopkins VTE Collaborative he spearheaded
efforts to develop evidence-based specialty-specific VTE Prophylaxis
computer decision support “smart order sets” that have led to dramatic
improvements in VTE prophylaxis across Johns Hopkins Medicine. Dr. Streiff
and the Anticoagulation Management Service team have played a key role in
developing evidence-based guidelines and electronic order sets for
anticoagulation therapy at Johns Hopkins Medical Institutions. He has
published over 100 articles and book chapters focusing on topics in VTE
management and thrombosis and hemostasis and delivered over 250 lectures at
local, national and international meetings.
Elizabeth Varga, MS, CGC; Columbus Children's Research Institute, Columbus, OH
Ms.
Varga is a Clinical Assistant Professor of Pediatrics at The Ohio State
University and a Certified Genetic Counselor at Nationwide Children’s
Hospital in Columbus, Ohio. She obtained her Bachelor of Science
degree in Biological Sciences at Depauw University and her Master of Science
in Medical Genetics from the University of Cincinnati. Ms. Varga has held
many roles in the genetic counseling profession, practicing in prenatal,
pediatric and adult settings as well as conducting research. She is widely
recognized for expertise related to thrombosis and thrombophilia,
specifically factor V Leiden. In addition to providing lectures to
various medical and lay audiences locally and nationally, Ms. Varga has
published several articles related to thrombophilia and serves on multiple
advisory committees. Ms. Varga is also a founding Board Member for the
National Blood Clot Alliance (NBCA) and has served as
Chair of the Education Committee since its inception. Ms. Varga serves
as a liaison to the Centers for Disease Control and Prevention to plan,
develop, and evaluate health promotion programs directed at individuals for
blood clots and clotting disorders.
Jeffrey Weitz, MD, Hamilton Regional Cancer Centre, Hamilton, Ontario
Dr.
Weitz is a Professor of Medicine and Biochemistry at McMaster University and
Director of the Henderson Research Centre. Board certified in Internal
Medicine, Hematology and Medical Oncology, Dr. Weitz now focuses his
clinical work in the area of thrombosis. He holds an Endowed Chair in
Cardiovascular Research at McMaster University, which is funded by the Heart
and Stroke Foundation of Ontario. He also holds the Canada Research Chair
(Tier 1) in Thrombosis. Dr. Weitz received the Medal in Medicine from the
Royal College of Physicians and Surgeons of Canada in 1991, the
Distinguished Scientist Award from the Heart and Stroke Foundation of
Ontario in 1999, the Research Achievement Award from the Canadian
Cardiovascular Society in 2006, and the Jack Hirsh Award for Outstanding
Academic Achievement from McMaster University in 2008. He is a member of
the American Federation of Medical Research, the American Society for
Clinical Investigation, and the Association of American Physicians and gave
the Davidson Lecture at the University of Edinburgh in 2000, the Nossel
Memorial Lecture at Columbia University in New York in 2003, and the
Mosesson Lecture at the Blood Research Institute in Milwaukee in 2008. Dr.
Weitz directs a well-funded research laboratory that focuses on the
biochemistry of blood coagulation and fibrinolysis as it applies to venous
and arterial thrombosis. A former Vice-President of Research for the Heart
and Stroke Foundation, member of the Board of Directors of the Heart and
Stroke Foundation of Ontario, Chair of the Scientific Review Committee for
the Heart and Stroke Foundation of Canada, member of the Executive Council
on Thrombosis of the American Heart Foundation, and Chair of the Council on
Vascular Biology for the American Society of Hematology, Dr. Weitz has
published over 265 peer-reviewed papers and 35 textbook chapters.
Home | About | Patient Education | HCP Resources | FAQs | Donate| | News | RSS Feeds | Contact | Site Map | Disclaimer | Links
Providing Healthcare Information on Blood Clots and Clotting Disorders®
Copyright © 2006 - 2013 All Rights Reserved - Stop the Clot® is a registered trade mark of the National Blood Clot Alliance
This page was last modified on .
